Durvalumab: Phase I started

Children’s Hospital Los Angeles began an open-label, U.S. Phase I trial to evaluate IV durvalumab every 2 weeks in about 36 patients ages 1-18 with solid tumors, including CNS tumors, and lymphoma. Du...